Skip to main content
. 2016 May;101(5):541–558. doi: 10.3324/haematol.2015.139337

Figure 7.

Figure 7.

Mutations in the kinase domain of ABL1 identified in tyrosine kinase inhibitors (TKI) resistant chronic myeloid leukemia cells. The 10 most frequent mutations, accounting for approximately 70% of TKI-resistant CML patients are highlighted in red.